KPV vs BPC-157
KPV and BPC-157 are two distinct research peptides that often appear together in the preclinical anti-inflammatory and tissue-repair literature. KPV is the three-amino-acid C-terminal fragment of α-MSH (Lys-Pro-Val); BPC-157 is a 15-amino-acid peptide derived from a protein found in gastric juice. They are related by the research areas they show up in — not by structure or origin — and neither is an approved drug.
The short answer
These two peptides are frequently mentioned in the same breath because both are studied in anti-inflammatory and tissue-repair research models. Structurally and mechanistically, though, they are quite different molecules: KPV is a minimal α-MSH-derived tripeptide studied mainly for anti-inflammatory signaling, while BPC-157 is a larger gastric-derived peptide whose literature emphasizes tissue, tendon, gastrointestinal, and angiogenesis models. Reading them side by side helps clarify what each is actually studied for — and keeps two separate compounds from being conflated.
What each one is
KPV
KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone — the α-MSH(11-13) fragment, with the sequence Lys-Pro-Val. Research interest centers on the observation that this very small fragment retains anti-inflammatory signaling associated with the parent hormone while being simpler and more stable than the full peptide. Because it is only three amino acids, it is inexpensive to synthesize and straightforward to characterize.
BPC-157
BPC-157 — "Body Protection Compound 157" — is a synthetic 15-amino-acid peptide (a pentadecapeptide) whose sequence is based on a partial sequence of a protein identified in gastric juice. It is not harvested from the body; research-grade material is manufactured to a defined sequence and verified against that specification. Its literature is dominated by animal and cell studies rather than controlled human trials.
Side-by-side specifications
| KPV | BPC-157 | |
|---|---|---|
| Class | α-MSH C-terminal tripeptide fragment | Synthetic gastric-derived pentadecapeptide |
| Sequence / length | Lys-Pro-Val — 3 amino acids | 15 amino acids (pentadecapeptide) |
| Origin | C-terminal fragment of α-MSH (α-MSH(11-13)) | Partial sequence of a protein found in gastric juice |
| CAS number | 67727-97-3 | 137525-51-0 |
| Molecular weight | 327.42 g/mol | 1419.55 g/mol |
| Purity (typical) | ≥99.0% by HPLC | ≥99% by HPLC |
| Research emphasis | Anti-inflammatory / NF-κB-associated signaling | Tissue, tendon, GI, and angiogenesis research |
| Form | White lyophilized powder; water-soluble | White lyophilized powder; water-soluble |
Values above reflect each compound's published specification. As with any research material, the definitive confirmation of identity and purity for a given lot is the mass-spectrometry and HPLC data on its Certificate of Analysis.
How their mechanisms and research emphases differ
The clearest way to tell these two apart is by what the literature actually studies. KPV is characterized as an anti-inflammatory peptide that appears to act on intracellular inflammatory signaling, including NF-κB-associated pathways. Much of its preclinical work sits in gastrointestinal-inflammation and colitis research models, epithelial and mucosal models, and comparisons against the parent α-MSH peptide. Its research center of gravity, in other words, is inflammation signaling.
BPC-157, by contrast, appears across a broader spread of models. Its literature emphasizes connective-tissue and tendon-injury models, gastrointestinal-tract models (reflecting its gastric origin), angiogenesis-associated signaling, and inflammation-related pathways. Where KPV is studied fairly narrowly around anti-inflammatory signaling, BPC-157 is discussed as a more multi-target peptide whose proposed mechanisms are still under investigation.
These are descriptions of what has been examined in laboratory and animal models — not claims that either peptide produces a particular effect in people. For both compounds the distance between preclinical signals and demonstrated human outcomes remains large, and neither has an established human use, dose, or safety profile.
Why they're discussed together
Given how different they are, why do KPV and BPC-157 so often appear side by side? The overlap is in research theme, not molecular identity. Both are studied in the context of inflammation and tissue repair, both are supplied to researchers as lyophilized powders, and both are frequently grouped under a general "recovery research" heading in vendor catalogs and discussion. That shared framing makes it easy to assume the two are interchangeable or complementary — but they are separate compounds with different sequences, origins, and mechanistic emphases. Any research design that references both should treat them as distinct materials, each with its own identity confirmation.
How they're characterized and tested
Both peptides are verified the same way as any research peptide: identity confirmed by mass spectrometry (does the measured mass match the expected value for the sequence?) and purity measured by HPLC, with both reported on a batch-specific Certificate of Analysis (COA). Because KPV and BPC-157 differ so sharply in molecular weight — roughly 327 g/mol versus roughly 1420 g/mol — the mass-spec value alone is an unambiguous way to confirm which compound is in a given vial. An independent, published COA lets a researcher verify identity and purity before beginning work. See peptide handling and storage for how samples are kept stable once received.
Common questions
Are KPV and BPC-157 the same thing?
No. They are distinct compounds. KPV is the α-MSH(11-13) tripeptide (Lys-Pro-Val); BPC-157 is a 15-amino-acid pentadecapeptide derived from a gastric protein. They share research themes, not structure or origin.
Why are KPV and BPC-157 discussed together?
Both appear in preclinical anti-inflammatory and tissue-repair research models, so the literature and vendor catalogs sometimes group them — even though they are studied for different signaling emphases.
Are KPV or BPC-157 approved for human use?
No. Neither is an FDA-approved drug, and research-grade material is for laboratory use only. KPV is among the peptides under FDA advisory review in 2026.